Delivery Order SPE2DB22D2007-SPE2DB25FJ4SU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120 count) under a firm fixed-price contract with a ceiling value of $1,131.87. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,273.70 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg, a testosterone replacement therapy medication. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 20, 2025. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $5,877.30 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on August 20, 2025, with completion scheduled for August 21, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $2,137.63 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg, a testosterone replacement therapy medication. This non-set-aside, competitively awarded contract was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and operates under a firm fixed price arrangement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order valued at $2,263.74 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Jatenzo is a testosterone replacement therapy medication used to treat hypogonadism in adult males,...
- The Defense Logistics Agency awarded a delivery order valued at $1,131.87 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Jatenzo is a testosterone replacement therapy indicated for hypogonadism treatment, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Jatenzo 198 mg capsules (120 count) valued at $1,798.32 under a firm fixed price contract type. The order was competitively awarded with no set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery from its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.67 to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120-count units) under a firm fixed-price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025. This is a non-set-aside contract, reflecting competitive procurement practices. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $1,131.87 delivery order to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 237 mg, a testosterone replacement therapy medication. This competitively awarded, firm fixed-price contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4SUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 158 mg capsules (120-count unit) under a firm fixed-price contract with a ceiling value of $1,983.45. The award, made on September 8, 2025, is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. This delivery order is executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime vehicle designated SPE2DX and running through December 2026, which provides comprehensive pharmaceutical support globally for military healthcare programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical vendor, particularly for the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates extensive experience supplying brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for testosterone replacement therapy medication represents a routine fulfillment under the company's established DLA framework, reflecting its ongoing capability to meet federal pharmaceutical procurement requirements through competitive processes and firm fixed-price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/8/25 |